Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 111

Results For "adult"

1344 News Found

USFDA approves Opdualag to treat metastatic melanoma
Drug Approval | March 19, 2022

USFDA approves Opdualag to treat metastatic melanoma

Opdualag is a first-in-class, fixed-dose dual immunotherapy combination treatment of the PD-1 inhibitor nivolumab and novel LAG-3-blocking antibody relatlimab


USFDA approves Rinvoq for ulcerative colitis
Drug Approval | March 17, 2022

USFDA approves Rinvoq for ulcerative colitis

First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology


Biological E gears up for new phase of vaccination drive
News | March 17, 2022

Biological E gears up for new phase of vaccination drive

To date, 30 crore vaccines have been produced as part of the commitment made to the Government of India


Bharat Biotech and Biofabri to develop and distribute novel TB vaccine
News | March 16, 2022

Bharat Biotech and Biofabri to develop and distribute novel TB vaccine

MTBVAC is a global public-private project that will be a milestone in the field of vaccinology


Moderna dosed the first participant for an experimental HIV trimer mRNA vaccine
News | March 14, 2022

Moderna dosed the first participant for an experimental HIV trimer mRNA vaccine

The open-label, multicenter, randomized Phase 1 trial is designed to evaluate the safety and immunogenicity of experimental HIV trimer mRNA vaccines


New data show Lynparza demonstrated overall survival benefit in early breast cancer
Biotech | March 12, 2022

New data show Lynparza demonstrated overall survival benefit in early breast cancer

Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial


China approves BeiGene’s tislelizumab
Drug Approval | March 12, 2022

China approves BeiGene’s tislelizumab

Tislelizumab is now approved for seven indications in China


Moderna begins Phase 2 study of Omicron-specific bivalent booster
Biotech | March 11, 2022

Moderna begins Phase 2 study of Omicron-specific bivalent booster

Moderna's Omicron-specific bivalent booster candidate combines its Omicron-specific booster candidate with its Covid-19 vaccine


AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment
Biotech | March 11, 2022

AbbVie’s Phase 3 data of Atogepant indicates positive outcome for migraine treatment

Data from this study will support a submission to expand the use of atogepant to include preventive treatment of chronic migraine in the United States and additional submissions globally


Strides receives USFDA approval for Colchicine tablets
Drug Approval | March 11, 2022

Strides receives USFDA approval for Colchicine tablets

Colchicine tablets are used for the treatment and prevention of gout. It reduces inflammation which causes pain, swelling and other symptoms of gout